Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Rectal Cancer treatment details. Chemotherapy. Aichi Cancer Center Hospital, Nagoya, Japan

Survival: 19.3 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: Japan
City/State/Province: Nagoya
Hospital: Aichi Cancer Center Hospital
Journal: Link
Date: 9/2010

This study involved patients with metastatic colorectal cancer. The patients were divided into 2 treatment groups. Group 1 included 213 patients with a median age of 63 years and 57.5% male. In group 2, which also included 213 patients, the median patient age was 61 years and 56.3% were male.

Patients in group 1 received a treatment regimen called FOLFIRI, which is a combination of the chemotherapy agents fluorouracil, folinic acid, and irinotecan.

Group 2 was given a treatment termed IRIS, which is a combination of the chemotherapy agents irinotecan and S-1.

There was one treatment-related death report for group 1, attributed to hypotension due to shock. Other reported toxicities reported for group 1 included grade 4 neutropenia (16.1% of patients) and grade 3 leucopenia (15.2%).

The maximum toxicity reported for group 2 was grade 4, including neutropenia (10.5% of patients) and leucopenia (2.9%). Grade 3 toxicities including diarrhea (20.5%), fatigue (8.6%), and anorexia (11.0%) were also reported.

The median overall survival in group 1 was 18.1 months and the median progression-free survival was 5.1 months.

For group 2, the median overall survival was 19.3 months and the median progression-free survival was 5.8 months.

This study was funded by the pharmaceutical companies Taiho Pharmaceutical Co. Ltd. And Daiichi Sankyo Co. Ltd.

Correspondence: Dr. Kei Muro; email:

E-mail to a Friend Email Physician More Information